When: Tuesday 27 July, 7-8 pm
Where: Online via Zoom - anywhere
This Breast Cancer Foundation NZ webinar looks what you need to know when being treated with Ibrance, from scheduling appointments, negotiating dosages and managing side effects.
Ibrance is a kind of drug called CDK4/6 inhibitor that has been publicly funded in New Zealand since April 2020. In this webinar, an expert panel will discuss how Ibrance is used in treatment for advanced breast cancer, managing common side effects and the practicalities of being on Ibrance.
This webinar may also be helpful for those taking Kisqali (ribociclib) and Verzenio (abemaciclib).
Meet the panel
Dr David Porter is a medical oncologist at Auckland City Hospital. He will discuss who is given Ibrance and when, and the clinical trial evidence around its use.
Karen Spells is a clinical nurse specialist working in oncology and with breast cancer patients. She will give advice on practicalities of appointments and tests and how to manage common side effects.
Cheryl Carr started Ibrance a few weeks ago, while Jacquie Dabrowski has been on Ibrance since 2018. They will share their experience of managing appointments, side effects and how it's impacted their lives.
Join the webinar on Tuesday 27 July and get your questions ready for the experts!